HCM HUTCHMED Year-over-year earnings per share growth for the last twelve months

HUTCHMED Ltd - graphic logo of issuer HCM

HUTCHMED (China) Limited (HCM) share price dynamics are largely independent of GDP, as demand for oncology therapy remains stable. Quarterly EPS growth on the GURU.Markets platform shows peaks, with the latest reading at -87.50. HUTCHMED (China) Limited attracts leading scientists by combining Eastern ethics with Western standards. High R&D costs are gradually offset by the global scaling of approved drugs.

HUTCHMED (HCM) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for HUTCHMED (HCM)

- share price and expert price forecast:
Comprehensive company analysis:HUTCHMED Ltd, HCM
Flagship merchandise of hutch-med.com

Asset managers require an objective tool to assess an issuer's financial stability. This indicator measures the dynamics of net earnings per share, filtering out market noise to highlight the true trajectory of profitability. By analyzing the quarterly EPS growth trend, an investor determines the business's ability to generate cash flow. For HUTCHMED (HCM), this growth confirms the effective commercialization of Fruquintinib. High barriers to switching protocols in oncology therapy make the positive dynamics of this metric a long-term driver of capitalization.

Who HUTCHMED (China) Limited competes with

Incyte Corporation (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months NUVB|DAWN (dayonebio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months monopartx.com (MNPR)|Year-over-year earnings per share growth for the last twelve months Inhibrx Corp (INBX)|IMAB - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc